1. A method of reducing or inhibiting angiogenesis in an individual suffering from an eye disease or condition associated with angiogenesis, comprising administering to the individual antagonist norrina.2. A method according to Claim. 1, wherein the Norrin antagonist is an antibody against norrina.3. . A method according to claim 1, wherein the disease or condition of the eye is selected from the group consisting of: diabetic retinopathy, choroidal neovascularization (CNV), age-related macular degeneration (AMD), diabetic macular edema (DME), pathological myopia, disease von Hippel -Lindau, ocular histoplasmosis, retinal vein occlusion central (CRVO), branch occlusion of the central retinal vein (BRVO), corneal neovascularization, retinal neovascularization, retinopathy of prematurity (ROP), subconjunctival hemorrhage, and hypertensive retinopa ii.4. A method according to claim. 3, wherein the eye disease is selected from the group consisting of diabetic retinopathy, AMD, DME, CRVO and BRVO.5. A method according to Claim. 1 further comprising administering a second anti-angiogenic agenta.6. The method of claim. 5, wherein the second anti-angiogenic agent is administered before or after administration of the antagonist norrina.7. The method of claim. 5, wherein the second anti-angiogenic agent is administered concurrently with antagonist norrina.8. A method according to claim. 5, wherein the second anti-angiogenic agent is an antagonist of factor vascular endothelial cell growth (VEGF) .9. A method according to claim. 8, wherein the VEGF antagonist is an antibody against VEGF.10. A method according to claim. 9, wherein the anti-VEGF represents ranibizumab.11. A method of treating an eye disease or condition associated with undesired angiogenesis in a subject, comprising administering1. Способ снижения или ингибирования ангиогенеза у индивидуума, страдающего заболеванием глаз или состоянием, ассоциированным с ангиогенезом, предусматривающий введение индивидууму антаго
